1Zeiher AM, Fisslthaler B, Schray-Utz B, et al. Nitric oxide modulates the. expression of monocyte chemoattractant protein 1 in cultured human endothelial cells [ J ]. Circ Res, 1995 ;76 ( 6 ) :980-6.
2Marin J, Rodriguez MA. Role of vascular nitric oxide in physiological and pathological conditions [ J ]. Pharmacol Ther, 1997 ;75 (2) : 111-34.
3Parker JD, Thiessen JJ. Increased endothelin-1 production with chronic heart failure[ J]. Int J Cardiol ,2004 ;93 (1) :63-8.
4Ledoux J, Gee DM, Leblanc N. Increased peripheral resistance in heart failure new evidence suggests an alteration in vascular smooth muscle function [ J ]. Br J Pharmacol, 2003 ; 139 ( 7 ) : 1245-8.
5Spinarova L, Vasku A, Goldbergova M, et al. Big endothelin in chronic heart failure: marker of disease severity or genetic determination[ J] ? Int J Cardiol,2004 ;93:63-8.
6Naruse K, Shimizu K, Muramatsu M. Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium dependent relaxation [ J ]. Arterioscler Thromb, 1994 ; 14 (5) :746-52.
8Bian K, Murad F. Nitric oxide (NO) - biogenration, regulation, and relevance to human disease. Front Biosci ,2003,8:264 -278.
9Stephane Cook. Coronary artery disease, nitric oxide and oxidative stress: the "Yin -Yang" effect- a Chinese concept for a worldwide pandemic. Swiss Med Wkly, 2006,136 : 103 - 113.
10Wilson SC. M yocardial endothelin: Does it play a role in myocardial faiLure? CircuLation, 1996,93 ( 6 ) : 1069.
